Menu

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
1/15/26 Compass Therapeutics (CMPX) tovecimig for Biliary Tract Cancer Subscribers Only Subscribers Only Subscribers Only
1/8/26 Eli Lilly (LLY) Mounjaro for Obesity Subscribers Only Subscribers Only Subscribers Only
1/8/26 Eli Lilly (LLY) Taltz for Obesity Subscribers Only Subscribers Only Subscribers Only
1/8/26 Ascendis Pharma (ASND) TransCon CNP for Achondroplasia Subscribers Only Subscribers Only Subscribers Only
1/7/26 Praxis (PRAX) relutrigine for Seizure Disorders (Epilepsy) Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
06/25/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
06/25/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
06/26/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
06/30/2025 Subscribers Only Subscribers Only Trial Announcement - Patient Enrollment Completed
09/08/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update